TheraRadar
← Back
Data updated: Jun 28, 2026

IVAX SUB TEVA PHARMS

Generics

IVAX SUB TEVA PHARMS is a generic drug manufacturer focused on Cardiovascular, Immunology, Infectious Disease.

1963
Since
109
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

IVAX SUB TEVA PHARMS's Key Drugs

IVAX SUB TEVA PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

IVAX SUB TEVA PHARMS's Therapeutic Areas

IVAX SUB TEVA PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 38%
9 drugs
Immunology 21%
5 drugs
Infectious Disease 17%
4 drugs
Dermatology 17%
4 drugs
Neurology 8%
2 drugs

IVAX SUB TEVA PHARMS's Top Competitors

IVAX SUB TEVA PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

IVAX SUB TEVA PHARMS Pipeline Snapshot

Active clinical trials for IVAX SUB TEVA PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling